Antibe Therapeutics (TSX:ATE) EV-to-EBITDA : 2.15 (As of May. 11, 2024)

View and export this data going back to 2013. Start your Free Trial

What is Antibe Therapeutics EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Antibe Therapeutics's enterprise value is C$-39.17 Mil. Antibe Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was C$-18.23 Mil. Therefore, Antibe Therapeutics's EV-to-EBITDA for today is 2.15.

The historical rank and industry rank for Antibe Therapeutics's EV-to-EBITDA or its related term are showing as below:

TSX:ATE' s EV-to-EBITDA Range Over the Past 10 Years
Min: -13.36 Med: -4.19 Max: 2.58
Current: 2.15

During the past 12 years, the highest EV-to-EBITDA of Antibe Therapeutics was 2.58. The lowest was -13.36. And the median was -4.19.

TSX:ATE's EV-to-EBITDA is ranked better than
61.47% of 462 companies
in the Biotechnology industry
Industry Median: 9.49 vs TSX:ATE: 2.15

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-11), Antibe Therapeutics's stock price is C$0.295. Antibe Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was C$-0.350. Therefore, Antibe Therapeutics's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.

Antibe Therapeutics EV-to-EBITDA Historical Data

The historical data trend for Antibe Therapeutics's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antibe Therapeutics EV-to-EBITDA Chart

Antibe Therapeutics Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

EV-to-EBITDA

Get a 7-Day Free Trial

-5.53

-9.75

-6.89

0.54

0.38

Antibe Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-EBITDA	Get a 7-Day Free Trial															0.83	0.38	0.52	0.11	-1.32

Competitive Comparison of Antibe Therapeutics's EV-to-EBITDA

For the Biotechnology subindustry, Antibe Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Antibe Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Antibe Therapeutics's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Antibe Therapeutics's EV-to-EBITDA falls into.

Antibe Therapeutics EV-to-EBITDA Calculation

Antibe Therapeutics's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA	=	Enterprise Value (Today)	/	EBITDA (TTM)
	=	-39.169	/	-18.234
	=	2.15

Antibe Therapeutics's current Enterprise Value is C$-39.17 Mil.
Antibe Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-18.23 Mil.

Antibe Therapeutics (TSX:ATE) EV-to-EBITDA Explanation

Antibe Therapeutics's PE Ratio for today is calculated as:

PE Ratio	=	Share Price (Today)	/	Earnings per Share (Diluted) (TTM)
	=	0.295	/	-0.350
	=	At Loss

Antibe Therapeutics's share price for today is C$0.295.
Antibe Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.350.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

Antibe Therapeutics EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Antibe Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Antibe Therapeutics (TSX:ATE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Antibe Therapeutics Inc (TSX:ATE) » Definitions » EV-to-EBITDA

Comparable Companies

Traded in Other Exchanges

ATBPF:USA

Address

15 Prince Arthur Avenue, Toronto, ON, CAN, M5R 1B2

Website

https://www.antibethera.com

Antibe Therapeutics Inc is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to target inflammation arising from a wide range of medical conditions. The company's pipeline includes assets that seek to overcome gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs. Antibe's lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids for post-operative pain. Antibe's second pipeline drug, ATB-352, is being developed for a specialized acute pain indication. The company's anticipated next target is inflammatory bowel disease, a condition long in need of safer, more effective therapies.

Antibe Therapeutics (TSX:ATE) Headlines

No Headlines